JP7756643B2 - Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 - Google Patents

Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Info

Publication number
JP7756643B2
JP7756643B2 JP2022540328A JP2022540328A JP7756643B2 JP 7756643 B2 JP7756643 B2 JP 7756643B2 JP 2022540328 A JP2022540328 A JP 2022540328A JP 2022540328 A JP2022540328 A JP 2022540328A JP 7756643 B2 JP7756643 B2 JP 7756643B2
Authority
JP
Japan
Prior art keywords
independently selected
alkyl
group
optionally substituted
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022540328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509422A5 (https=
JPWO2021138434A5 (https=
JP2023509422A (ja
Inventor
ハンス マルティン ザイデル
ウィリアム アール． ルーシュ
シャンカル ベンカトラマン
ジェーソン カッツ
Original Assignee
ノバルティス ファーマ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ファーマ アーゲー filed Critical ノバルティス ファーマ アーゲー
Publication of JP2023509422A publication Critical patent/JP2023509422A/ja
Publication of JP2023509422A5 publication Critical patent/JP2023509422A5/ja
Publication of JPWO2021138434A5 publication Critical patent/JPWO2021138434A5/ja
Application granted granted Critical
Publication of JP7756643B2 publication Critical patent/JP7756643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022540328A 2019-12-31 2020-12-30 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 Active JP7756643B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955839P 2019-12-31 2019-12-31
US62/955,839 2019-12-31
US202063090538P 2020-10-12 2020-10-12
US63/090,538 2020-10-12
PCT/US2020/067483 WO2021138434A1 (en) 2019-12-31 2020-12-30 Compounds and compositions for treating conditions associated with sting activity

Publications (4)

Publication Number Publication Date
JP2023509422A JP2023509422A (ja) 2023-03-08
JP2023509422A5 JP2023509422A5 (https=) 2024-01-11
JPWO2021138434A5 JPWO2021138434A5 (https=) 2024-01-11
JP7756643B2 true JP7756643B2 (ja) 2025-10-20

Family

ID=74206237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540328A Active JP7756643B2 (ja) 2019-12-31 2020-12-30 Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物

Country Status (8)

Country Link
US (1) US20230127839A1 (https=)
EP (1) EP4085051A1 (https=)
JP (1) JP7756643B2 (https=)
CN (2) CN120965654A (https=)
PY (1) PY2089159A (https=)
TW (1) TW202136239A (https=)
UY (1) UY39006A (https=)
WO (1) WO2021138434A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823036B (zh) 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
WO2022140397A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
US20240060982A1 (en) 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN117756698A (zh) * 2022-12-16 2024-03-26 中国药科大学 脲类化合物及其作为sting抑制剂的医药用途
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
CN120794982A (zh) * 2024-05-14 2025-10-17 中国药科大学 吡唑类sting抑制剂及其医药用途
CN120794957A (zh) * 2024-05-14 2025-10-17 中国药科大学 苯并含氮杂环类sting抑制剂及其医药用途
WO2026023667A1 (ja) * 2024-07-25 2026-01-29 カルナバイオサイエンス株式会社 フェニルピペラジン誘導体

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512967A (ja) 2001-09-26 2005-05-12 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
JP2008540598A (ja) 2005-05-18 2008-11-20 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 鎮痛剤としての置換されたベンゾ［ｄ］イソオキサゾール−３−イル−アミン化合物
JP2010503702A (ja) 2006-09-14 2010-02-04 デシファラ ファーマスーティカルズ， エルエルシー 増殖性疾患の治療に有用なキナーゼ阻害剤
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
CN102516153A (zh) 2011-12-14 2012-06-27 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
JP2013545740A (ja) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
JP2016534030A (ja) 2013-06-11 2016-11-04 カラ ファーマシューティカルズ インコーポレイテッド 尿素誘導体及びその使用
CN107417478A (zh) 2017-06-05 2017-12-01 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
WO2019201939A1 (en) 2018-04-16 2019-10-24 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5783558A (en) * 1980-11-13 1982-05-25 Asahi Chem Ind Co Ltd Novel organic compound and its preparation
JPS5783557A (en) * 1980-11-14 1982-05-25 Asahi Chem Ind Co Ltd Novel azomethine compound and its preparation
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
WO2020191227A1 (en) * 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
EP4267128A1 (en) * 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4267129A1 (en) * 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
WO2022140397A1 (en) * 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
US20240060982A1 (en) * 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
JP2005512967A (ja) 2001-09-26 2005-05-12 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
JP2008540598A (ja) 2005-05-18 2008-11-20 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 鎮痛剤としての置換されたベンゾ［ｄ］イソオキサゾール−３−イル−アミン化合物
JP2010503702A (ja) 2006-09-14 2010-02-04 デシファラ ファーマスーティカルズ， エルエルシー 増殖性疾患の治療に有用なキナーゼ阻害剤
JP2013545740A (ja) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
CN102516153A (zh) 2011-12-14 2012-06-27 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
JP2016534030A (ja) 2013-06-11 2016-11-04 カラ ファーマシューティカルズ インコーポレイテッド 尿素誘導体及びその使用
CN107417478A (zh) 2017-06-05 2017-12-01 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
WO2019201939A1 (en) 2018-04-16 2019-10-24 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DJUNG, J. F. et al.，The synthesis and evaluation of indolylureas as PKCα inhibitors，Bioorganic & Medicinal Chemistry，2011年，Vol.19, No.8，pp.2742-2750，DOI:10.1016/j.bmc.2011.02.036
HAAG, S. M. et al.，Targeting STING with covalent small-molecule inhibitors，Nature，2018年，Vol.559, No.7713，pp.269-273，DOI:10.1038/s41586-018-0287-8
RAFFA, D. et al.，Synthesis and antiproliferative activity of 3-amino-N-phenyl-1H-indazole-1-carboxamides，European Journal of Medicinal Chemistry，2009年，Vol.44, No.1，pp.165-178，DOI:10.1016/j.ejmech.2008.03.023
VADIVELAN, S. et al.，Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors，Journal of Chemical Information and Modeling，2007年，Vol.47, No.4，pp.1526-1535，DOI:10.1021/ci7000742

Also Published As

Publication number Publication date
UY39006A (es) 2021-07-30
TW202136239A (zh) 2021-10-01
PY2089159A (es) 2022-05-11
EP4085051A1 (en) 2022-11-09
CN115348957A (zh) 2022-11-15
CN115348957B (zh) 2025-11-25
JP2023509422A (ja) 2023-03-08
US20230127839A1 (en) 2023-04-27
CN120965654A (zh) 2025-11-18
WO2021138434A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
JP7756643B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7566731B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP7482122B2 (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TWI873145B (zh) 用於治療與sting活性相關之病狀的化合物及組合物
JP2023509421A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2025066719A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2023540673A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2023540672A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2021067805A1 (en) Oxalamide heterobycyclic compounds and compositions for treating conditions associated with sting activity
JP2022535743A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024502474A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
JP2023540674A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024502472A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2023554393A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2022015938A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2024502470A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
WO2023137034A1 (en) Compounds and compositions for treating conditions associated with sting activity
WO2024151919A1 (en) Compounds and compositions for treating conditions associated with sting activity
JP2023554392A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2024502473A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するためのオキサルアミド化合物および組成物
JP2024532798A (ja) Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
JP2025504415A (ja) Ｓｔｉｎｇ活性に関連する病態を治療するための化合物及び組成物
HK40107251A (zh) 用於治疗与sting活性有关的疾病的化合物和组合物
CN118119595A (zh) 用于治疗与sting活性有关的疾病的化合物和组合物
HK40048003B (zh) 用於治疗与sting活性有关的疾病的化合物和组合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231226

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241018

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250306

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A59 Written plea

Free format text: JAPANESE INTERMEDIATE CODE: A59

Effective date: 20250326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251007

R150 Certificate of patent or registration of utility model

Ref document number: 7756643

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150